JP2023500532A5 - - Google Patents
Info
- Publication number
- JP2023500532A5 JP2023500532A5 JP2022526073A JP2022526073A JP2023500532A5 JP 2023500532 A5 JP2023500532 A5 JP 2023500532A5 JP 2022526073 A JP2022526073 A JP 2022526073A JP 2022526073 A JP2022526073 A JP 2022526073A JP 2023500532 A5 JP2023500532 A5 JP 2023500532A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1916210.6 | 2019-11-07 | ||
| GBGB1916210.6A GB201916210D0 (en) | 2019-11-07 | 2019-11-07 | High purity tryptamines and methods of synthesis thereof |
| GB1917320.2 | 2019-11-28 | ||
| GBGB1917320.2A GB201917320D0 (en) | 2019-11-28 | 2019-11-28 | Novel compounds |
| GB2008303.6A GB2585978B (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions |
| GB2008303.6 | 2020-06-02 | ||
| PCT/EP2020/081503 WO2021089873A1 (en) | 2019-11-07 | 2020-11-09 | Method of synthesis |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023500532A JP2023500532A (ja) | 2023-01-06 |
| JPWO2021089873A5 JPWO2021089873A5 (https=) | 2023-02-02 |
| JP2023500532A5 true JP2023500532A5 (https=) | 2023-02-02 |
| JP7422473B2 JP7422473B2 (ja) | 2024-01-26 |
Family
ID=75849570
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526073A Active JP7422473B2 (ja) | 2019-11-07 | 2020-11-09 | 合成方法 |
| JP2022526074A Active JP7423131B2 (ja) | 2019-11-07 | 2020-11-09 | 化合物 |
| JP2023202672A Active JP7748437B2 (ja) | 2019-11-07 | 2023-11-30 | 化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526074A Active JP7423131B2 (ja) | 2019-11-07 | 2020-11-09 | 化合物 |
| JP2023202672A Active JP7748437B2 (ja) | 2019-11-07 | 2023-11-30 | 化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US11643390B2 (https=) |
| EP (3) | EP3873883B1 (https=) |
| JP (3) | JP7422473B2 (https=) |
| KR (2) | KR20220082092A (https=) |
| CN (2) | CN114829341B (https=) |
| AU (2) | AU2020378647B2 (https=) |
| BR (1) | BR112022008919A2 (https=) |
| CA (2) | CA3160337C (https=) |
| DK (1) | DK3844147T3 (https=) |
| ES (2) | ES2940811T3 (https=) |
| HR (2) | HRP20220797T1 (https=) |
| HU (2) | HUE059403T2 (https=) |
| IL (2) | IL292754B2 (https=) |
| MX (1) | MX2022005399A (https=) |
| NZ (1) | NZ788543A (https=) |
| PL (2) | PL3873883T3 (https=) |
| PT (2) | PT3873883T (https=) |
| WO (2) | WO2021089873A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP7422473B2 (ja) * | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| US11332441B2 (en) * | 2020-03-23 | 2022-05-17 | Caamtech, Inc. | Crystalline N-methyl tryptamine derivatives |
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| AU2021204158B2 (en) * | 2020-06-02 | 2023-03-02 | Cybin Uk Ltd | Deuterated compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| WO2021250435A1 (en) | 2020-06-12 | 2021-12-16 | Beckley Psytech Limited | Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| IL308816A (en) | 2021-05-25 | 2024-01-01 | Atai Therapeutics Inc | New n,n-dimethyltryptamine salts and crystalline salt forms |
| MX2023014620A (es) | 2021-06-09 | 2024-01-30 | Atai Therapeutics Inc | Nuevos profarmacos y conjugados de dimetiltriptamina. |
| EP4122916A1 (en) * | 2021-07-22 | 2023-01-25 | GH Research Ireland Limited | Method for preparing an organic compound |
| KR20240132439A (ko) * | 2021-07-22 | 2024-09-03 | 지에이치 리서치 아일랜드 리미티드 | 트립타민 유도체의 제조 방법 |
| US11697638B2 (en) * | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
| MX2024005955A (es) | 2021-11-18 | 2024-06-11 | Cybin Uk Ltd | Formulaciones inyectables e inhalables. |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| WO2023108174A1 (en) * | 2021-12-10 | 2023-06-15 | Terran Biosciences, Inc. | Analogs of 6-methoxy- n, n-dimethyltryptamine |
| JP2024545787A (ja) | 2021-12-30 | 2024-12-11 | アタイ セラピューティクス， インコーポレイテッド | 一酸化窒素送達剤としてのジメチルトリプタミン類似体 |
| WO2023147423A1 (en) * | 2022-01-28 | 2023-08-03 | Miralogx Llc | Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US20230346718A1 (en) * | 2022-04-27 | 2023-11-02 | Yale University | Method of treating, ameliorating and/or preventing depression |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| US12264131B2 (en) * | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| CN120344243A (zh) | 2022-10-13 | 2025-07-18 | 赛本英国有限公司 | 包含致幻剂的胃肠外制剂的施用方法 |
| EP4618981A1 (en) | 2022-11-17 | 2025-09-24 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| TW202430149A (zh) * | 2022-12-01 | 2024-08-01 | 美商雅特益醫療公司 | Ｎ，ｎ－二甲基色胺之結晶形式及其使用方法 |
| WO2024156713A1 (en) | 2023-01-23 | 2024-08-02 | Cybin Uk Ltd | Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent |
| AU2024242138A1 (en) | 2023-03-31 | 2025-11-13 | Cybin Uk Ltd | Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| US12157722B1 (en) * | 2023-08-03 | 2024-12-03 | Gilgamesh Pharmaceuticals, Inc. | Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| US12129234B1 (en) * | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| WO2026013174A1 (en) | 2024-07-10 | 2026-01-15 | Cybin Uk Ltd | Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336378A (en) | 1980-04-10 | 1982-06-22 | Sandoz, Inc. | Isoxazolyl indolamines |
| EP0593513B1 (en) * | 1991-06-21 | 1998-10-28 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-ht1-like receptors or 5-ht2 receptor agonistes |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| EP2036540A3 (en) | 2000-06-16 | 2009-12-16 | Jagotec AG | Improved injectable dispersions of propofol |
| WO2004085392A1 (en) | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
| JP2010507585A (ja) | 2006-10-19 | 2010-03-11 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換インドール |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| CZ302424B6 (cs) * | 2007-06-13 | 2011-05-11 | Zentiva, A. S. | Zpusob prípravy almotriptanu o vysoké cistote |
| MX2010001390A (es) * | 2007-08-06 | 2010-08-02 | Synosia Therapeutics Inc | Métodos para el tratamiento de dependencia. |
| US20090076121A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched sumatriptan |
| US20090093513A1 (en) | 2007-10-09 | 2009-04-09 | Hamann Mark T | Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter |
| US20100113496A1 (en) | 2008-09-25 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of vmat2 |
| EP2771341A4 (en) | 2011-10-28 | 2015-09-23 | Univ Texas | NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| CN104684555A (zh) | 2012-09-18 | 2015-06-03 | 奥斯拜客斯制药有限公司 | 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学 |
| MX370188B (es) * | 2013-03-14 | 2019-12-04 | Dart Neuroscience Cayman Ltd | Compuestos de piridina y pirazina sustituidos como inhibidores de pde4. |
| EP3628640B1 (en) | 2014-09-02 | 2023-08-09 | Hub Therapeutics | Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment |
| US10336703B2 (en) * | 2015-05-12 | 2019-07-02 | Council Of Scientific And Industrial Research | Process for the synthesis of ivacaftor and related compounds |
| WO2018064465A1 (en) * | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| CA3052974A1 (en) | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| US20200147038A1 (en) | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| WO2019089902A1 (en) | 2017-11-01 | 2019-05-09 | Drexel University | Compounds, compositions, and methods for treating diseases |
| MD3927338T2 (ro) | 2019-02-22 | 2025-03-31 | Gh Res Ireland Limited | Compoziții cuprinzând 5-metoxi-N,N-dimetiltriptamină (5-MeO-DMT) pentru utilizare în tratarea tulburărilor mentale |
| EP4353314A3 (en) | 2019-02-22 | 2024-07-03 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression |
| AU2020228289B2 (en) * | 2019-02-27 | 2026-02-05 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| CN113784962B (zh) | 2019-02-27 | 2025-04-25 | 加利福尼亚大学董事会 | 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环 |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP7422473B2 (ja) | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| CN111072492A (zh) * | 2019-11-29 | 2020-04-28 | 浙江工业大学 | 一种合成3,4-二氯-2-氨基-5-氟联苯的方法 |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| CN116056705A (zh) | 2020-08-05 | 2023-05-02 | 巴塞尔大学医院 | 用于dmt辅助心理疗法的静脉内dmt施用方法 |
| WO2022043227A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US20220062237A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| JP2023544724A (ja) | 2020-10-02 | 2023-10-25 | サイビン アイアールエル リミテッド | 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| WO2022117640A1 (en) | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Inhalable formulations |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| IL303288A (en) | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | N,N-Dimethyltryptamine compounds partially or fully deuterated |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
-
2020
- 2020-11-09 JP JP2022526073A patent/JP7422473B2/ja active Active
- 2020-11-09 CN CN202080087092.5A patent/CN114829341B/zh active Active
- 2020-11-09 EP EP20816375.8A patent/EP3873883B1/en active Active
- 2020-11-09 CN CN202080087091.0A patent/CN114829340B/zh active Active
- 2020-11-09 DK DK20816376.6T patent/DK3844147T3/da active
- 2020-11-09 AU AU2020378647A patent/AU2020378647B2/en active Active
- 2020-11-09 HR HRP20220797TT patent/HRP20220797T1/hr unknown
- 2020-11-09 EP EP20816376.6A patent/EP3844147B1/en active Active
- 2020-11-09 ES ES20816375T patent/ES2940811T3/es active Active
- 2020-11-09 HR HRP20230281TT patent/HRP20230281T1/hr unknown
- 2020-11-09 WO PCT/EP2020/081503 patent/WO2021089873A1/en not_active Ceased
- 2020-11-09 NZ NZ788543A patent/NZ788543A/en unknown
- 2020-11-09 IL IL292754A patent/IL292754B2/en unknown
- 2020-11-09 PT PT208163758T patent/PT3873883T/pt unknown
- 2020-11-09 HU HUE20816376A patent/HUE059403T2/hu unknown
- 2020-11-09 MX MX2022005399A patent/MX2022005399A/es unknown
- 2020-11-09 JP JP2022526074A patent/JP7423131B2/ja active Active
- 2020-11-09 PL PL20816375.8T patent/PL3873883T3/pl unknown
- 2020-11-09 EP EP22214748.0A patent/EP4180037A1/en active Pending
- 2020-11-09 AU AU2020381103A patent/AU2020381103B2/en active Active
- 2020-11-09 PL PL20816376.6T patent/PL3844147T3/pl unknown
- 2020-11-09 CA CA3160337A patent/CA3160337C/en active Active
- 2020-11-09 KR KR1020227018623A patent/KR20220082092A/ko not_active Ceased
- 2020-11-09 HU HUE20816375A patent/HUE061482T2/hu unknown
- 2020-11-09 CA CA3160334A patent/CA3160334C/en active Active
- 2020-11-09 WO PCT/EP2020/081502 patent/WO2021089872A1/en not_active Ceased
- 2020-11-09 PT PT208163766T patent/PT3844147T/pt unknown
- 2020-11-09 KR KR1020237033500A patent/KR20230142817A/ko not_active Ceased
- 2020-11-09 BR BR112022008919A patent/BR112022008919A2/pt not_active Application Discontinuation
- 2020-11-09 IL IL292753A patent/IL292753B2/en unknown
- 2020-11-09 ES ES20816376T patent/ES2920681T3/es active Active
-
2021
- 2021-08-26 US US17/412,828 patent/US11643390B2/en active Active
-
2022
- 2022-05-06 US US17/662,261 patent/US11578039B2/en active Active
-
2023
- 2023-01-10 US US18/152,465 patent/US12157723B2/en active Active
- 2023-03-31 US US18/193,866 patent/US12084417B2/en active Active
- 2023-11-30 JP JP2023202672A patent/JP7748437B2/ja active Active
-
2024
- 2024-03-12 US US18/602,171 patent/US20240217929A1/en active Pending
- 2024-10-21 US US18/921,515 patent/US20250042852A1/en active Pending